Screening of Bufadienolides from Toad Venom Identifies Gammabufotalin as a Potential Anti-inflammatory Agent,Planta Medica

当前位置： X-MOL 学术 › Planta Med. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Screening of Bufadienolides from Toad Venom Identifies Gammabufotalin as a Potential Anti-inflammatory Agent
Planta Medica ( IF 2.1 ) Pub Date : 2020-10-13 , DOI: 10.1055/a-1248-2626
Yuanru Zheng _{1,

2} , Lijuan Deng ₃ , Huihui Cao _{1,

2} , Nishan Xu _{1,

2} , Dongmei Zhang ₄ , Haiyan Tian ₄ , Baojing Li ₅ , Zibin Lu _{1,

2} , Wencai Ye ₄ , Linzhong Yu _{1,

2} , Chunlin Fan ₄ , Junshan Liu _{1,

2}

Affiliation

Toad venom (Chansu) is used in the treatment of infectious and inflammatory diseases in China and East/Southeast Asian countries. However, the anti-inflammatory components of toad venom have not yet been systematically evaluated and clearly defined. To investigate the anti-inflammatory effects of toad venom and identify new anti-inflammatory ingredients, we used zebrafish, an alternative drug screening model, to evaluate the anti-inflammatory effects of 14 bufadienolides previously isolated from toad venom. Most of the bufadienolides were found to exert significant anti-inflammatory effects on lipopolysaccharide-, CuSO4-, or tail transection-induced zebrafish inflammatory models. Moreover, gammabufotalin ( 6: ) inhibits lipopolysaccharide-induced inflammation by suppressing the myeloid differentiation primary response 88/nuclear factor-kappa B and STAT3 signal pathways. This study confirms the potential of zebrafish in drug screening, clarifies the anti-inflammatory effects of bufadienolides from toad venom, and indicates that gammabufotalin may be developed as a novel therapeutic agent for inflammatory diseases in the future.

更新日期：2020-10-13

点击分享查看原文

点击收藏

公开下载

阅读更多本刊新发论文本刊介绍/投稿指南